Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Drug discovery 2012-09, Vol.11 (9), p.730-730 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 730 |
|---|---|
| container_issue | 9 |
| container_start_page | 730 |
| container_title | Nature reviews. Drug discovery |
| container_volume | 11 |
| creator | Orchard, Sandra Al-Lazikani, Bissan Bryant, Steve Clark, Dominic Calder, Elizabeth Dix, Ian Engkvist, Ola Forster, Mark Gaulton, Anna Gilson, Michael Glen, Robert Grigorov, Martin Hammond-Kosack, Kim Harland, Lee Hopkins, Andrew Larminie, Christopher Lynch, Nick Mann, Romeena K. Murray-Rust, Peter Piparo, Elena Lo Southan, Christopher Steinbeck, Christoph Wishart, David Hermjakob, Henning Overington, John Thornton, Janet |
| description | |
| doi_str_mv | 10.1038/nrd3503-c2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1037310398</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A302402818</galeid><sourcerecordid>A302402818</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-c912ce5799cc063465b7d24a4225c37ed5e9d23c1403ea56e0c6b46d45eb28db3</originalsourceid><addsrcrecordid>eNptkVtrFTEUhYeiYK2--AsCfSgoU3ObycyTHEtvUBGsPg-ZnT2nKSfJmGSEPvjfm9NTrEUJJDvhW2vtJFX1jtFjRkX30UcjGipq4HvVPpNK1kx18sWfWrWvqtcp3VLKWqb4fvX7-iYsG-OPMkGvfbbBYbRA5iXafEdGJNbDZjFoSkHyDZIjZ711iyv7KUSni8QTPYYlE01GGzRk-wuLWy4Gn8g3THPwCckUg3sw-HK5-nxK1jEs85vq5aQ3Cd8-rgfVj7PT7ycX9dXX88uT1VUNolG5hp5xwEb1PQBthWybURkuteS8AaHQNNgbLoBJKlA3LVJoR9ka2eDIOzOKg-pw5zvH8HPBlIfbsERfIofybEqUqe-eqLXe4LC9Xo4anE0wrATlkvKObanj_1BlGHQWgsfJlvNngvc7AcSQUsRpmKN1Ot6V7G18Nzz-2gC8wB92cCqQX2P8u9N_6Hue65iY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1037310398</pqid></control><display><type>article</type><title>Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group</title><source>Nature</source><source>SpringerLink Journals - AutoHoldings</source><creator>Orchard, Sandra ; Al-Lazikani, Bissan ; Bryant, Steve ; Clark, Dominic ; Calder, Elizabeth ; Dix, Ian ; Engkvist, Ola ; Forster, Mark ; Gaulton, Anna ; Gilson, Michael ; Glen, Robert ; Grigorov, Martin ; Hammond-Kosack, Kim ; Harland, Lee ; Hopkins, Andrew ; Larminie, Christopher ; Lynch, Nick ; Mann, Romeena K. ; Murray-Rust, Peter ; Piparo, Elena Lo ; Southan, Christopher ; Steinbeck, Christoph ; Wishart, David ; Hermjakob, Henning ; Overington, John ; Thornton, Janet</creator><creatorcontrib>Orchard, Sandra ; Al-Lazikani, Bissan ; Bryant, Steve ; Clark, Dominic ; Calder, Elizabeth ; Dix, Ian ; Engkvist, Ola ; Forster, Mark ; Gaulton, Anna ; Gilson, Michael ; Glen, Robert ; Grigorov, Martin ; Hammond-Kosack, Kim ; Harland, Lee ; Hopkins, Andrew ; Larminie, Christopher ; Lynch, Nick ; Mann, Romeena K. ; Murray-Rust, Peter ; Piparo, Elena Lo ; Southan, Christopher ; Steinbeck, Christoph ; Wishart, David ; Hermjakob, Henning ; Overington, John ; Thornton, Janet</creatorcontrib><identifier>ISSN: 1474-1776</identifier><identifier>EISSN: 1474-1784</identifier><identifier>DOI: 10.1038/nrd3503-c2</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/154/309 ; 706/648/453 ; 706/648/479 ; 92 ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Cancer Research ; Medicinal Chemistry ; Molecular Medicine ; Pharmaceutical research ; Pharmacology/Toxicology ; reply</subject><ispartof>Nature reviews. Drug discovery, 2012-09, Vol.11 (9), p.730-730</ispartof><rights>Springer Nature Limited 2012</rights><rights>COPYRIGHT 2012 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Sep 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-c912ce5799cc063465b7d24a4225c37ed5e9d23c1403ea56e0c6b46d45eb28db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nrd3503-c2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nrd3503-c2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids></links><search><creatorcontrib>Orchard, Sandra</creatorcontrib><creatorcontrib>Al-Lazikani, Bissan</creatorcontrib><creatorcontrib>Bryant, Steve</creatorcontrib><creatorcontrib>Clark, Dominic</creatorcontrib><creatorcontrib>Calder, Elizabeth</creatorcontrib><creatorcontrib>Dix, Ian</creatorcontrib><creatorcontrib>Engkvist, Ola</creatorcontrib><creatorcontrib>Forster, Mark</creatorcontrib><creatorcontrib>Gaulton, Anna</creatorcontrib><creatorcontrib>Gilson, Michael</creatorcontrib><creatorcontrib>Glen, Robert</creatorcontrib><creatorcontrib>Grigorov, Martin</creatorcontrib><creatorcontrib>Hammond-Kosack, Kim</creatorcontrib><creatorcontrib>Harland, Lee</creatorcontrib><creatorcontrib>Hopkins, Andrew</creatorcontrib><creatorcontrib>Larminie, Christopher</creatorcontrib><creatorcontrib>Lynch, Nick</creatorcontrib><creatorcontrib>Mann, Romeena K.</creatorcontrib><creatorcontrib>Murray-Rust, Peter</creatorcontrib><creatorcontrib>Piparo, Elena Lo</creatorcontrib><creatorcontrib>Southan, Christopher</creatorcontrib><creatorcontrib>Steinbeck, Christoph</creatorcontrib><creatorcontrib>Wishart, David</creatorcontrib><creatorcontrib>Hermjakob, Henning</creatorcontrib><creatorcontrib>Overington, John</creatorcontrib><creatorcontrib>Thornton, Janet</creatorcontrib><title>Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group</title><title>Nature reviews. Drug discovery</title><addtitle>Nat Rev Drug Discov</addtitle><subject>631/154/309</subject><subject>706/648/453</subject><subject>706/648/479</subject><subject>92</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Cancer Research</subject><subject>Medicinal Chemistry</subject><subject>Molecular Medicine</subject><subject>Pharmaceutical research</subject><subject>Pharmacology/Toxicology</subject><subject>reply</subject><issn>1474-1776</issn><issn>1474-1784</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkVtrFTEUhYeiYK2--AsCfSgoU3ObycyTHEtvUBGsPg-ZnT2nKSfJmGSEPvjfm9NTrEUJJDvhW2vtJFX1jtFjRkX30UcjGipq4HvVPpNK1kx18sWfWrWvqtcp3VLKWqb4fvX7-iYsG-OPMkGvfbbBYbRA5iXafEdGJNbDZjFoSkHyDZIjZ711iyv7KUSni8QTPYYlE01GGzRk-wuLWy4Gn8g3THPwCckUg3sw-HK5-nxK1jEs85vq5aQ3Cd8-rgfVj7PT7ycX9dXX88uT1VUNolG5hp5xwEb1PQBthWybURkuteS8AaHQNNgbLoBJKlA3LVJoR9ka2eDIOzOKg-pw5zvH8HPBlIfbsERfIofybEqUqe-eqLXe4LC9Xo4anE0wrATlkvKObanj_1BlGHQWgsfJlvNngvc7AcSQUsRpmKN1Ot6V7G18Nzz-2gC8wB92cCqQX2P8u9N_6Hue65iY</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Orchard, Sandra</creator><creator>Al-Lazikani, Bissan</creator><creator>Bryant, Steve</creator><creator>Clark, Dominic</creator><creator>Calder, Elizabeth</creator><creator>Dix, Ian</creator><creator>Engkvist, Ola</creator><creator>Forster, Mark</creator><creator>Gaulton, Anna</creator><creator>Gilson, Michael</creator><creator>Glen, Robert</creator><creator>Grigorov, Martin</creator><creator>Hammond-Kosack, Kim</creator><creator>Harland, Lee</creator><creator>Hopkins, Andrew</creator><creator>Larminie, Christopher</creator><creator>Lynch, Nick</creator><creator>Mann, Romeena K.</creator><creator>Murray-Rust, Peter</creator><creator>Piparo, Elena Lo</creator><creator>Southan, Christopher</creator><creator>Steinbeck, Christoph</creator><creator>Wishart, David</creator><creator>Hermjakob, Henning</creator><creator>Overington, John</creator><creator>Thornton, Janet</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20120901</creationdate><title>Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group</title><author>Orchard, Sandra ; Al-Lazikani, Bissan ; Bryant, Steve ; Clark, Dominic ; Calder, Elizabeth ; Dix, Ian ; Engkvist, Ola ; Forster, Mark ; Gaulton, Anna ; Gilson, Michael ; Glen, Robert ; Grigorov, Martin ; Hammond-Kosack, Kim ; Harland, Lee ; Hopkins, Andrew ; Larminie, Christopher ; Lynch, Nick ; Mann, Romeena K. ; Murray-Rust, Peter ; Piparo, Elena Lo ; Southan, Christopher ; Steinbeck, Christoph ; Wishart, David ; Hermjakob, Henning ; Overington, John ; Thornton, Janet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-c912ce5799cc063465b7d24a4225c37ed5e9d23c1403ea56e0c6b46d45eb28db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>631/154/309</topic><topic>706/648/453</topic><topic>706/648/479</topic><topic>92</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Cancer Research</topic><topic>Medicinal Chemistry</topic><topic>Molecular Medicine</topic><topic>Pharmaceutical research</topic><topic>Pharmacology/Toxicology</topic><topic>reply</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orchard, Sandra</creatorcontrib><creatorcontrib>Al-Lazikani, Bissan</creatorcontrib><creatorcontrib>Bryant, Steve</creatorcontrib><creatorcontrib>Clark, Dominic</creatorcontrib><creatorcontrib>Calder, Elizabeth</creatorcontrib><creatorcontrib>Dix, Ian</creatorcontrib><creatorcontrib>Engkvist, Ola</creatorcontrib><creatorcontrib>Forster, Mark</creatorcontrib><creatorcontrib>Gaulton, Anna</creatorcontrib><creatorcontrib>Gilson, Michael</creatorcontrib><creatorcontrib>Glen, Robert</creatorcontrib><creatorcontrib>Grigorov, Martin</creatorcontrib><creatorcontrib>Hammond-Kosack, Kim</creatorcontrib><creatorcontrib>Harland, Lee</creatorcontrib><creatorcontrib>Hopkins, Andrew</creatorcontrib><creatorcontrib>Larminie, Christopher</creatorcontrib><creatorcontrib>Lynch, Nick</creatorcontrib><creatorcontrib>Mann, Romeena K.</creatorcontrib><creatorcontrib>Murray-Rust, Peter</creatorcontrib><creatorcontrib>Piparo, Elena Lo</creatorcontrib><creatorcontrib>Southan, Christopher</creatorcontrib><creatorcontrib>Steinbeck, Christoph</creatorcontrib><creatorcontrib>Wishart, David</creatorcontrib><creatorcontrib>Hermjakob, Henning</creatorcontrib><creatorcontrib>Overington, John</creatorcontrib><creatorcontrib>Thornton, Janet</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Nature reviews. Drug discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orchard, Sandra</au><au>Al-Lazikani, Bissan</au><au>Bryant, Steve</au><au>Clark, Dominic</au><au>Calder, Elizabeth</au><au>Dix, Ian</au><au>Engkvist, Ola</au><au>Forster, Mark</au><au>Gaulton, Anna</au><au>Gilson, Michael</au><au>Glen, Robert</au><au>Grigorov, Martin</au><au>Hammond-Kosack, Kim</au><au>Harland, Lee</au><au>Hopkins, Andrew</au><au>Larminie, Christopher</au><au>Lynch, Nick</au><au>Mann, Romeena K.</au><au>Murray-Rust, Peter</au><au>Piparo, Elena Lo</au><au>Southan, Christopher</au><au>Steinbeck, Christoph</au><au>Wishart, David</au><au>Hermjakob, Henning</au><au>Overington, John</au><au>Thornton, Janet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group</atitle><jtitle>Nature reviews. Drug discovery</jtitle><stitle>Nat Rev Drug Discov</stitle><date>2012-09-01</date><risdate>2012</risdate><volume>11</volume><issue>9</issue><spage>730</spage><epage>730</epage><pages>730-730</pages><issn>1474-1776</issn><eissn>1474-1784</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><doi>10.1038/nrd3503-c2</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-1776 |
| ispartof | Nature reviews. Drug discovery, 2012-09, Vol.11 (9), p.730-730 |
| issn | 1474-1776 1474-1784 |
| language | eng |
| recordid | cdi_proquest_journals_1037310398 |
| source | Nature; SpringerLink Journals - AutoHoldings |
| subjects | 631/154/309 706/648/453 706/648/479 92 Biomedical and Life Sciences Biomedicine Biotechnology Cancer Research Medicinal Chemistry Molecular Medicine Pharmaceutical research Pharmacology/Toxicology reply |
| title | Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T19%3A15%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Shouldn't%20enantiomeric%20purity%20be%20included%20in%20the%20'minimum%20information%20about%20a%20bioactive%20entity?%20Response%20from%20the%20MIABE%20group&rft.jtitle=Nature%20reviews.%20Drug%20discovery&rft.au=Orchard,%20Sandra&rft.date=2012-09-01&rft.volume=11&rft.issue=9&rft.spage=730&rft.epage=730&rft.pages=730-730&rft.issn=1474-1776&rft.eissn=1474-1784&rft_id=info:doi/10.1038/nrd3503-c2&rft_dat=%3Cgale_proqu%3EA302402818%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1037310398&rft_id=info:pmid/&rft_galeid=A302402818&rfr_iscdi=true |